EOLS
Price
$9.35
Change
+$0.15 (+1.63%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
846.82M
13 days until earnings call
NBIX
Price
$134.97
Change
+$1.48 (+1.11%)
Updated
Jul 17, 02:51 PM (EDT)
Capitalization
13.72B
13 days until earnings call
Interact to see
Advertisement

EOLS vs NBIX

Header iconEOLS vs NBIX Comparison
Open Charts EOLS vs NBIXBanner chart's image
Evolus
Price$9.35
Change+$0.15 (+1.63%)
Volume$14.13K
Capitalization846.82M
Neurocrine Biosciences
Price$134.97
Change+$1.48 (+1.11%)
Volume$100
Capitalization13.72B
EOLS vs NBIX Comparison Chart in %
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. NBIX commentary
Jul 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a Hold and NBIX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 17, 2025
Stock price -- (EOLS: $9.20 vs. NBIX: $133.48)
Brand notoriety: EOLS and NBIX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EOLS: 61% vs. NBIX: 86%
Market capitalization -- EOLS: $846.82M vs. NBIX: $13.72B
EOLS [@Pharmaceuticals: Other] is valued at $846.82M. NBIX’s [@Pharmaceuticals: Other] market capitalization is $13.72B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • EOLS’s TA Score: 4 bullish, 3 bearish.
  • NBIX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than NBIX.

Price Growth

EOLS (@Pharmaceuticals: Other) experienced а -4.76% price change this week, while NBIX (@Pharmaceuticals: Other) price change was -0.02% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.83%. For the same industry, the average monthly price growth was +5.67%, and the average quarterly price growth was +73.81%.

Reported Earning Dates

EOLS is expected to report earnings on Nov 11, 2025.

NBIX is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.83% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than EOLS($847M). NBIX YTD gains are higher at: -2.212 vs. EOLS (-16.667). NBIX has higher annual earnings (EBITDA): 358M vs. EOLS (-41.81M). NBIX has more cash in the bank: 1.03B vs. EOLS (62.8M). EOLS has less debt than NBIX: EOLS (127M) vs NBIX (428M). NBIX has higher revenues than EOLS: NBIX (1.89B) vs EOLS (202M).
EOLSNBIXEOLS / NBIX
Capitalization847M13.7B6%
EBITDA-41.81M358M-12%
Gain YTD-16.667-2.212753%
P/E RatioN/A57.20-
Revenue202M1.89B11%
Total Cash62.8M1.03B6%
Total Debt127M428M30%
FUNDAMENTALS RATINGS
EOLS vs NBIX: Fundamental Ratings
EOLS
NBIX
OUTLOOK RATING
1..100
771
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
7182
SMR RATING
1..100
10061
PRICE GROWTH RATING
1..100
8250
P/E GROWTH RATING
1..100
10034
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (72) in the Biotechnology industry is in the same range as EOLS (89) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as NBIX (82) in the Biotechnology industry. This means that EOLS’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's SMR Rating (61) in the Biotechnology industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew somewhat faster than EOLS’s over the last 12 months.

NBIX's Price Growth Rating (50) in the Biotechnology industry is in the same range as EOLS (82) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

NBIX's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew significantly faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSNBIX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
61%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 21 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ULE13.010.06
+0.46%
ProShares Ultra Euro
KSEP25.880.12
+0.46%
Innovator U.S. Small Cp Pwr Buf ETF -Sep
BUFG25.760.10
+0.39%
FT Vest Buffered Allocation Gr ETF
PEY20.990.08
+0.38%
Invesco High Yield Eq Div Achiev™ ETF
MSTI20.56N/A
N/A
Madison Short-Term Strategic Income ETF

NBIX and

Correlation & Price change

A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+1.71%
LFCR - NBIX
33%
Poorly correlated
-0.13%
EOLS - NBIX
30%
Poorly correlated
-0.76%
ELAN - NBIX
30%
Poorly correlated
-0.68%
CGC - NBIX
29%
Poorly correlated
+0.92%
TLRY - NBIX
27%
Poorly correlated
+1.58%
More